종양학 기반 생체내 CRO 시장 보고서 : 적응증, 모델, 용도, 지역별(2026-2034년)

The global oncology based in-vivo CRO market size reached USD 1.4 Billion in 2025. Looking forward, IMARC Group expects the market to reach USD 2.5 Billion by 2034, exhibiting a growth rate (CAGR) of 6.29% during 2026-2034. The rising prevalence of cancer, regulatory compliances, ongoing technological advancements, and the surging demand for personalized medicines are driving the market growth.

ONCOLOGY BASED IN-VIVO CRO MARKET ANALYSIS:

• Major Market Drivers: The growing prevalence of cancer around the world represents one of the key factors driving the market. Moreover, governments of several countries across the globe are extensively investing in research and development (R&D) activities, which is driving industry's growth.
• Key Market Trends: The wide availability of personalized treatment techniques, along with the expanding healthcare industry, is catalyzing the demand for oncology based in-vivo CRO worldwide. Additionally, there is an increase in the adoption of telehealth and virtual clinical trials in the healthcare industry to ensure the safety of cancer patients. This is projected to bolster the growth of the market.
• Competitive Landscape: Some of the prominent oncology based in-vivo CRO market companies in the market include Champions Oncology Inc., Charles River Laboratories International Inc., Crown Bioscience Inc., Eurofins Scientific, Evotec SE, ICON Plc, Labcorp Drug Development (Laboratory Corporation of America Holdings), Living Tumor Laboratory, Taconic Biosciences Inc., The Jackson Laboratory, WuXi AppTec, and Xentech, among many others.
• Geographical Trends: According to the oncology based in-vivo CRO market dynamics, North America exhibits a clear dominance in the market. The prevalence of various types of cancer continues to increase in the region, driving oncology based in-vivo CRO market demand.
• Challenges and Opportunities: Regulatory and compliance burden, and the increasing demand for customized clinical trial protocols are hampering the market growth. However, AI-driven algorithms for data analytics, predictive modeling, and patient stratification enhance efficiency and decision-making in oncology research.

ONCOLOGY BASED IN-VIVO CRO MARKET TRENDS:

Rising Prevalence of Cancer

The rising prevalence of cancer is a significant driver behind the growth of the oncology-based in-vivo Contract Research Organization (CRO) market. Cancer continues to be a major public health challenge worldwide, with increasing incidence rates across various types of cancers. For instance, the IARC's 2022 study showed around 20 million new cancer cases and nearly nine million deaths worldwide, with lung and breast cancer being the most common. Similarly, according to an article published by the Union for International Cancer Control, cancer cases are projected to rise to 35 million by 2050. The complexity of cancer requires tailored treatment approaches, leading to a higher demand for clinical trials and research services provided by CROs. These factors are positively influencing the oncology based in-vivo CRO market revenue.

Increasing Emphasis on Personalized Medicine

The increasing emphasis on personalized medicine is a major driver behind the growth and evolution of the oncology-based in-vivo Contract Research Organization (CRO) market. For instance, according to Statista, personalized medical care, medicines, and diagnostics were estimated to account for around 40% of total revenue in 2022. Oncology is the most significant therapeutic area for personalized medicine. Tailoring treatments to individual patients improves efficacy, reduces adverse effects, and enhances overall treatment outcomes, driving the demand for CROs with expertise in personalized medicine, thereby positively influencing the oncology based in-vivo CRO industry forecast.

Technological Advancements

Increasing technological advancements are escalating the demand for oncology-based in-vivo Contract Research Organizations. Improved imaging modalities, such as PET-CT, MRI, and molecular imaging techniques have enabled better visualization and monitoring of tumors in vivo. For instance, in June 2024, Siemens Healthineers launched the Biograph Trinion, their latest PET/CT scanner, at the annual meeting of the Society of Nuclear Medicine and Molecular Imaging. The scanner's detector is based on lutetium oxyorthosilicate (LSO) crystal elements and delivers high spatial resolution and an ultrafast time-of-flight performance of 239 picoseconds for small lesion detectability and effective sensitivity up to 128 cps/kBq, allowing for fast scans and low patient radiation doses. This enhances the ability to track disease progression and response to treatments more accurately. These factors are further bolstering the oncology-based in-vivo CRO market revenue.

GLOBAL ONCOLOGY BASED IN-VIVO CRO INDUSTRY SEGMENTATION:

Breakup by Indication:

• Blood Cancer
• Solid Tumors
• Others

Solid tumors currently represent the largest market share

According to the oncology-based in-vivo CRO market outlook, solid tumors are the most common type of cancer, encompassing a wide range of malignancies such as breast, lung, colorectal, and prostate cancers. Their prevalence ensures a large patient population for clinical trials, making them attractive for CROs and pharmaceutical companies. Moreover, there has been a significant increase in the number of cancer patients. For instance, the American Cancer Society, the major source of cancer statistics and data, estimated nearly 1,685,210 new cancer cases and 595,690 deaths in the United States in 2021.

Breakup by Model:

• Syngeneic
• Xenograft
• Patient Derived Xenograft (PDX)
• Others

Currently, Patient Derived Xenograft (PDX) model accounts for the majority of the total market share

According to the oncology-based in-vivo CRO market overview, PDX models involve implanting patient-derived tumor tissue into immunodeficient mice, thereby preserving the molecular and histological characteristics of the original tumor. This model closely mimics human tumor biology and heterogeneity, making it invaluable for studying cancer progression, metastasis, and treatment response. Moreover, these models are highly predictive of patient response to therapies, including chemotherapy, targeted therapy, and immunotherapy. Pharmaceutical companies and biotech firms rely on PDX studies to assess drug efficacy, optimize treatment regimens, and identify potential biomarkers for patient stratification.

Breakup by Application:

• Hospitals
• Rehabilitation Centers

The oncology-based in-vivo CRO market report has provided a detailed breakup and analysis of the market based on the application. This includes hospitals and rehabilitation centers.

Hospitals frequently collaborate with CROs to conduct clinical trials for evaluating new oncology treatments. CROs provide expertise in study design, protocol development, patient recruitment, and regulatory compliance, enabling hospitals to participate in cutting-edge research without diverting resources from patient care. While rehabilitation centers may participate in clinical trials focused on cancer survivors who require rehabilitation services to improve their quality of life post-treatment. CROs can support such trials by providing expertise in study design, outcome measures, and data management specific to this patient population.

Breakup by Region:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America currently dominates the global market

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.

According to the oncology based in-vivo CRO market statistics, the rising incidence of cancer cases in North America continues to drive demand for innovative therapies and treatment options. For instance, the Globocan 2021 report estimated that nearly 2,281,000 new cancer cases were diagnosed in the United States in 2021, with almost 612,000 fatalities. Oncology-focused CROs play a critical role in advancing research and development efforts to address unmet medical needs across various cancer types. Moreover, continuous advancements in technology, including molecular profiling, genomic sequencing, imaging modalities (such as PET-CT and MRI), and high-throughput screening platforms, enhance the capabilities of CROs to conduct sophisticated in-vivo studies. These technologies enable precise characterization of tumors, identification of biomarkers, and evaluation of therapeutic efficacy, contributing to the growth of oncology based CRO services.

COMPETITIVE LANDSCAPE:

The market research report has provided a comprehensive analysis of the competitive landscape. Detailed profiles of all major market companies have also been provided. Some of the key players in the market include:

• Champions Oncology Inc.
• Charles River Laboratories International Inc.
• Crown Bioscience Inc.
• Eurofins Scientific
• Evotec SE
• ICON Plc
• Labcorp Drug Development (Laboratory Corporation of America Holdings)
• Living Tumor Laboratory
• Taconic Biosciences Inc.
• The Jackson Laboratory
• WuXi AppTec
• Xentech

KEY QUESTIONS ANSWERED IN THIS REPORT

1. What was the size of the global oncology based in-vivo CRO market in 2025?

2. What is the expected growth rate of the global oncology based in-vivo CRO market during 2026-2034?

3. What are the key factors driving the global oncology based in-vivo CRO market?

4. What has been the impact of COVID-19 on the global oncology based in-vivo CRO market?

5. What is the breakup of the global oncology based in-vivo CRO market based on the indication?

6. What is the breakup of the global oncology based in-vivo CRO market based on the model?

7. What are the key regions in the global oncology based in-vivo CRO market?

8. Who are the key players/companies in the global oncology based in-vivo CRO market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Oncology Based In-Vivo CRO Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Indication

• 6.1 Blood Cancer
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Solid Tumors
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Others
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast

7 Market Breakup by Model

• 7.1 Syngeneic
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Xenograft
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Patient Derived Xenograft (PDX)
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Others
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast

8 Market Breakup by Application

• 8.1 Hospitals
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Rehabilitation Centers
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Champions Oncology Inc.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
    • 14.3.1.3 Financials
  • 14.3.2 Charles River Laboratories International Inc.
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
    • 14.3.2.3 Financials
    • 14.3.2.4 SWOT Analysis
  • 14.3.3 Crown Bioscience Inc.
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Eurofins Scientific
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
    • 14.3.4.4 SWOT Analysis
  • 14.3.5 Evotec SE
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
    • 14.3.5.4 SWOT Analysis
  • 14.3.6 ICON Plc
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 Labcorp Drug Development (Laboratory Corporation of America Holdings)
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 SWOT Analysis
  • 14.3.8 Living Tumor Laboratory
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Taconic Biosciences Inc.
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 The Jackson Laboratory
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
  • 14.3.11 WuXi AppTec
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
  • 14.3.12 Xentech
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio